Zanrong Pharmaceutical Technology Co., Ltd. today announced an agreement with Roche to acquire the global rights to ZN-A-1041, an oral small molecule HER2 inhibitor. Zanrong

Freya Pharma Solutions, a pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced

Bruker Corporation today announced that is has closed the acquisition of ZONTAL Inc. an innovative platform provider for the digital transformation of the analytical laboratory,

Ascletis Pharma Inc. announces today that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus

Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has signed an option agreement with BGN

XNK Therapeutics AB today announced that the company's autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor

Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility. The 27,000 square foot good manufacturing practice (GMP) compliant facility